Beckman Coulter to Issue $500M in New Debt for Olympus Dx Acquisition | GenomeWeb

NEW YORK (GenomeWeb News) – Beckman Coulter today said that it would pay for the $800 million acquisition of Olympus' diagnostics business through a combination of around $300 million in Beckman Coulter stock and $500 million in newly issued debt.

The firm finished the year with roughly $120 million in cash and cash equivalents and around $900 million in long-term debt. However, Beckman said today that it does not anticipate a change in its current investment grade ratings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.